These monocytes, which lose BCL2 expression and preferentially rely on MCL1 for survival, show outgrowth in relapsed/refractory AML and have a distinct immunopathogenic signature (CD45-bright/SSChigh/CD117-/CD11b+/CD68+) that might allow early detection and therapeutic decision making[167]. Here, BCL2 is linked to acute myeloid leukemia.